Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myeloma
•
Hematology
What is your approach to first-line treatment of light chain deposition disease?
Do you treat similar to Amyloid, e.g. with Dara-CyBor-D
Related Questions
Under what circumstances is it okay to initiate treatment for suspected multiple myeloma without a bone marrow biopsy?
How do you approach the second-line treatment for a patient with high-risk myeloma relapse early post-autoHCT after Dara-RVD induction?
What is your approach to bone imaging in MGUS?
What is your re-immunization strategy after auto SCT for patients with myeloma on dara/len maintenance?
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
What is your preferred dose and schedule for maintenance drugs post autoHCT for newly diagnosed multiple myeloma?
In a patient with cardiac light chain amyloid who has significant heart failure symptoms, including inotrope dependence at presentation, how much clinical benefit does treatment provide?
In an adult patient with asymptomatic, isolated neutropenia in whom you suspect a Duffy null phenotype, at what ANC or in what situations would you do a bone marrow to look for other etiologies of neutropenia?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
